相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cyclopropavir Susceptibility of Cytomegalovirus DNA Polymerase Mutants Selected after Antiviral Drug Exposure
Sunwen Chou et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
In Vitro Evaluation of the Activities of the Novel Anticytomegalovirus Compound AIC246 (Letermovir) against Herpesviruses and Other Human Pathogenic Viruses
Manfred Marschall et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Factors Contributing to Variability of Quantitative Viral PCR Results in Proficiency Testing Samples: a Multivariate Analysis
R. T. Hayden et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2012)
Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis
Guy Boivin et al.
JOURNAL OF CLINICAL VIROLOGY (2012)
Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis
A. P. Wiita et al.
TRANSPLANT INFECTIOUS DISEASE (2012)
Clinical Utility of Cytomegalovirus Cell-Mediated Immunity in Transplant Recipients With Cytomegalovirus Viremia
Luiz F. Lisboa et al.
TRANSPLANTATION (2012)
Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: 1-Year Results of a Randomized Clinical Trial
Oliver Witzke et al.
TRANSPLANTATION (2012)
Cytomegalovirus in Solid Organ Transplantation: Epidemiology, Prevention, and Treatment
Elena Beam et al.
CURRENT INFECTIOUS DISEASE REPORTS (2012)
First Report of Successful Treatment of Multidrug-Resistant Cytomegalovirus Disease with the Novel Anti-CMV Compound AIC246
D. R. Kaul et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
Cytomegalovirus Incidence Between Everolimus Versus Mycophenolate in De Novo Renal Transplants: Pooled Analysis of Three Clinical Trials
D. C. Brennan et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation
Dana G. Wolf et al.
ANTIVIRAL RESEARCH (2011)
Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: A single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial
C. Ashley Finlen Copeland et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2011)
The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase
Thomas Goldner et al.
JOURNAL OF VIROLOGY (2011)
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial
Paul D. Griffiths et al.
LANCET (2011)
The risk of cytomegalovirus recurrence after kidney transplantation
Ilkka Helantera et al.
TRANSPLANT INTERNATIONAL (2011)
The Clinical Utility of Whole Blood Versus Plasma Cytomegalovirus Viral Load Assays for Monitoring Therapeutic Response
Luiz F. Lisboa et al.
TRANSPLANTATION (2011)
Incidence and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infections in 1244 Kidney Transplant Recipients
Hans-Arne Myhre et al.
TRANSPLANTATION (2011)
Progress in the development of new therapies for herpesvirus infections
Nathan B. Price et al.
CURRENT OPINION IN VIROLOGY (2011)
Clinical Predictors of Relapse after Treatment of Primary Gastrointestinal Cytomegalovirus Disease in Solid Organ Transplant Recipients
A. J. Eid et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients
A. Humar et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
Extended Valganciclovir Prophylaxis to Prevent Cytomegalovirus After Lung Transplantation
Scott M. Palmer et al.
ANNALS OF INTERNAL MEDICINE (2010)
Cytomegalovirus Seroprevalence in the United States: The National Health and Nutrition Examination Surveys, 1988-2004
Sheri Lewis Bate et al.
CLINICAL INFECTIOUS DISEASES (2010)
Antiviral Drug Resistance of Human Cytomegalovirus
Nell S. Lurain et al.
CLINICAL MICROBIOLOGY REVIEWS (2010)
New Developments in the Management of Cytomegalovirus Infection after Solid Organ Transplantation
Albert J. Eid et al.
DRUGS (2010)
Direct and indirect effects of cytomegalovirus: can we prevent them?
Raymund Razonable
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA (2010)
Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection
Michael J. Cannon et al.
REVIEWS IN MEDICAL VIROLOGY (2010)
Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients
R. K. Avery et al.
TRANSPLANT INFECTIOUS DISEASE (2010)
A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+and CD8+T cells in kidney allograft recipients at risk of CMV infection
Albert J. Eid et al.
TRANSPLANT INTERNATIONAL (2010)
Extended Valganciclovir Prophylaxis in D+/R- Kidney Transplant Recipients is Associated With Long-Term Reduction in Cytomegalovirus Disease: Two-Year Results of the IMPACT Study
Atul Humar et al.
TRANSPLANTATION (2010)
Utility of Leflunomide in the Treatment of Complex Cytomegalovirus Syndromes
Robin K. Avery et al.
TRANSPLANTATION (2010)
An Assessment of Herpesvirus Co-infections in Patients with CMV Disease: Correlation with Clinical and Virologic Outcomes
A. Humar et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
Interlaboratory Comparison of Cytomegalovirus Viral Load Assays
X. L. Pang et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
Cell-Mediated Immunity to Predict Cytomegalovirus Disease in High-Risk Solid Organ Transplant Recipients
D. Kumar et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients
A. Asberg et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
An Assessment of Donor-to-Recipient Transmission Patterns of Human Cytomegalovirus by Analysis of Viral Genomic Variants
Oriol Manuel et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation
N. W. Cummins et al.
TRANSPLANT INFECTIOUS DISEASE (2009)
Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial
V. Kliem et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation
Giuseppe Gerna et al.
TRANSPLANTATION (2008)
Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes
Albert J. Eid et al.
CLINICAL TRANSPLANTATION (2008)
Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients
A. Asberg et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2007)
Cytomegalovirus-associated allograft rejection in heart transplant patients
Luciano Potena et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2007)
Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: A meta-analysis comparing prophylactic and preemptive therapies
Lorne N. Small et al.
CLINICAL INFECTIOUS DISEASES (2006)
Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients
J. A. Khoury et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients
M. Green et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
American society of transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation
A Humar et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients
AC Kalil et al.
ANNALS OF INTERNAL MEDICINE (2005)
A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients
A Humar et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients
A Humar et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir
FM Mattes et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients
C Paya et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients
A Humar et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients
LS Munoz-Price et al.
CLINICAL INFECTIOUS DISEASES (2004)
Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation
MR Zamora et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients
G Boivin et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Cardiac allograft vasculopathy after heart transplantation: Risk factors and management
H Valantine
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2004)
Comparison of LightCycler-based PCR, COBAS Amplicor CMV monitor, and pp65 antigenemia assays for quantitative measurement of cytomegalovirus viral load in peripheral blood specimens from patients after solid organ transplantation
XLL Pang et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2003)
Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir
RR Razonable et al.
JOURNAL OF INFECTIOUS DISEASES (2003)
Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients
SM Bhorade et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2002)
Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease
A Humar et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
Controversies in lung transplantation: Management of cytomegalovirus infections
MR Zamora
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2002)
Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts
VC Emery et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients
E Mylonakis et al.
CLINICAL INFECTIOUS DISEASES (2002)
Definitions of cytomegalovirus infection and disease in transplant recipients
P Ljungman et al.
CLINICAL INFECTIOUS DISEASES (2002)
The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease
RR Razonable et al.
TRANSPLANTATION (2002)
High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy
AP Limaye et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients
RR Razonable et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2002)
Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir
RR Razonable et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: A multicenter, open-label study
DR Snydman et al.
TRANSPLANTATION PROCEEDINGS (2001)
Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants
AP Limaye et al.
LANCET (2000)
Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation
VC Emery et al.
LANCET (2000)
Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation
IG Sia et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
分享论文
